Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world.
The company was founded in 2018 and is headquartered in Emeryville, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 14, 2022 | Corporate Round | $80M | 1 | Ionis Pharmaceuticals | — | Detail |
Jan 25, 2022 | Series B | $175M | 18 |
Farallon Capital Management
PFM Health Sciences |
— | Detail |
May 27, 2021 | Grant | $600K | 1 | Cystic Fibrosis Foundation | — | Detail |
Nov 12, 2020 | Series A | $75M | 7 |
Humboldt Fund
Leaps by Bayer RA Capital Management |
— | Detail |
Aug 16, 2019 | Series A | $26.37M | 7 |
Bayer
Humboldt Fund |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Ionis Pharmaceuticals | Yes | Corporate Round |
Farallon Capital Management | Yes | Series B |
PFM Health Sciences | Yes | Series B |
Cystic Fibrosis Foundation | Yes | Grant |
Bayer | Yes | Series A |
Bristol Myers Squibb | — | Series B |
Deep Track Capital | — | Series B |
Eventide | — | Series B |
Frazier Healthcare Partners | — | Series B |
HOF Capital | — | Series B |